How faulty sodium channels cause dangerous heart rhythms
A Versatile Chemical-Genetic Approach to Determine Bases for Arrhythmogenesis and Sodium Channelopathies
Researchers are using a chemical-genetic method to temporarily switch off a heart sodium channel to learn why some gene changes lead to dangerous arrhythmias in people with inherited sodium channel disorders.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project ID | NIH-11237184 on NIH RePORTER |
What this research studies
The team engineered the heart sodium channel NaV1.5 to carry a drug-specific binding site so a small molecule can rapidly and reversibly silence that channel in tissue. They use this chemical-genetic tool in lab-grown cells and animal models to mimic loss-of-function SCN5A changes while avoiding developmental compensations seen in traditional genetic models. This approach helps separate the effects of NaV1.5 from other cardiac or brain sodium channels and clarifies how reduced channel activity triggers arrhythmias like Brugada syndrome. Results will guide where to target future therapies and improve interpretation of patient genetic variants.
Who could benefit from this research
Good fit: People with Brugada syndrome or other inherited SCN5A-related sodium channel disorders, especially those with known SCN5A mutations, would be the most relevant patient group for future related clinical efforts.
Not a fit: Patients whose arrhythmias are unrelated to sodium channel defects or who lack SCN5A mutations are unlikely to see direct benefit from this preclinical research in the near term.
Why it matters
Potential benefit: If successful, this work could pinpoint how SCN5A mutations cause arrhythmias and guide more precise, safer treatments for Brugada syndrome and related sodium channel disorders.
How similar studies have performed: Prior genetic and animal models have clarified some sodium channel roles, but this isoform-specific, reversible chemical-genetic silencing approach is novel and has not yet been proven in humans.
Where this research is happening
Iowa City, United States
- University of Iowa — Iowa City, United States (Active)
Researchers
- Principal investigator: Ahern, Christopher a — University of Iowa
- Study coordinator: Ahern, Christopher a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.